MX2012011938A - Compuesto para tratamiento de condicion o enfermedad respiratoria. - Google Patents
Compuesto para tratamiento de condicion o enfermedad respiratoria.Info
- Publication number
- MX2012011938A MX2012011938A MX2012011938A MX2012011938A MX2012011938A MX 2012011938 A MX2012011938 A MX 2012011938A MX 2012011938 A MX2012011938 A MX 2012011938A MX 2012011938 A MX2012011938 A MX 2012011938A MX 2012011938 A MX2012011938 A MX 2012011938A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- disease
- compound
- respiratory condition
- exacerbations
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000005713 exacerbation Effects 0.000 abstract 1
- 230000004199 lung function Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2010901601A AU2010901601A0 (en) | 2010-04-15 | Compound for the treatment of respiratory condition or disease | |
| PCT/AU2011/000434 WO2011127538A1 (en) | 2010-04-15 | 2011-04-14 | Compound for treatment of respiratory condition or disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012011938A true MX2012011938A (es) | 2013-01-28 |
Family
ID=44788654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012011938A MX2012011938A (es) | 2010-04-15 | 2011-04-14 | Compuesto para tratamiento de condicion o enfermedad respiratoria. |
Country Status (16)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014251442A1 (en) | 2013-04-12 | 2015-12-03 | Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
| JP2017518325A (ja) | 2014-06-20 | 2017-07-06 | アビラジェン セラピューティクス インコーポレイテッドＡｖｉｒａｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ６−｛２−［１−（６−メチル−３−ピリダジニル）−４−ピペリジニル］エトキシ｝−３−エトキシ−１，２−ベンゾイソオキサゾールの無水結晶性遊離塩基形態 |
| WO2024192151A2 (en) * | 2023-03-13 | 2024-09-19 | Altesa BioSciences, Inc. | Method of dosing vapendavir to treat enterovirus infections |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR213700A0 (en) * | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
| CA2475971A1 (en) * | 2002-02-14 | 2003-08-21 | Viropharma Incorporated | Methods of reducing rhinovirus contagion and related compositions |
| EP1596859B1 (en) * | 2003-02-21 | 2008-07-02 | Apodemus AB | Treatment of diseases caused by ljungan virus by using pleconaril |
| US9308199B2 (en) * | 2004-04-29 | 2016-04-12 | Honeywell International Inc. | Medicament formulations |
| WO2006029182A2 (en) * | 2004-09-07 | 2006-03-16 | The La Jolla Institute For Molecular Medicine | Use of mdl-100,907 for treatment of allergic and eosinophil mediated diseases |
| AR057623A1 (es) * | 2005-11-28 | 2007-12-05 | Omega Bio Pharma H K Ltd | Materiales y metodos para el tratamiento de las infecciones virales |
| AU2009253738B2 (en) * | 2008-05-27 | 2012-12-13 | Biota Scientific Management Pty Ltd | Antiviral salts |
| TW201016215A (en) * | 2008-07-17 | 2010-05-01 | Schering Corp | Compositions and uses of antiviral active pharmaceutical agents |
-
2011
- 2011-04-14 EA EA201201416A patent/EA025224B1/ru not_active IP Right Cessation
- 2011-04-14 CN CN2011800192025A patent/CN102844032A/zh active Pending
- 2011-04-14 CA CA2796207A patent/CA2796207A1/en not_active Abandoned
- 2011-04-14 NZ NZ60304011A patent/NZ603040A/en not_active IP Right Cessation
- 2011-04-14 ES ES11768285.6T patent/ES2647223T3/es active Active
- 2011-04-14 CN CN201510982692.9A patent/CN105560245A/zh active Pending
- 2011-04-14 EP EP11768285.6A patent/EP2558097B1/en not_active Not-in-force
- 2011-04-14 JP JP2013504064A patent/JP6148618B2/ja active Active
- 2011-04-14 MX MX2012011938A patent/MX2012011938A/es not_active Application Discontinuation
- 2011-04-14 KR KR1020127029232A patent/KR20130106267A/ko not_active Ceased
- 2011-04-14 SG SG10201502391WA patent/SG10201502391WA/en unknown
- 2011-04-14 BR BR112012026244A patent/BR112012026244A2/pt not_active IP Right Cessation
- 2011-04-14 WO PCT/AU2011/000434 patent/WO2011127538A1/en not_active Ceased
- 2011-04-14 SG SG2012073565A patent/SG184430A1/en unknown
- 2011-04-14 AU AU2011241478A patent/AU2011241478B2/en not_active Ceased
- 2011-04-15 US US13/087,624 patent/US20110257192A1/en not_active Abandoned
-
2012
- 2012-10-09 IL IL222244A patent/IL222244A0/en unknown
- 2012-10-12 ZA ZA2012/07696A patent/ZA201207696B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201201416A1 (ru) | 2013-03-29 |
| EP2558097A1 (en) | 2013-02-20 |
| SG184430A1 (en) | 2012-11-29 |
| EA025224B1 (ru) | 2016-12-30 |
| WO2011127538A1 (en) | 2011-10-20 |
| BR112012026244A2 (pt) | 2016-07-12 |
| EP2558097A4 (en) | 2013-09-11 |
| IL222244A0 (en) | 2012-12-31 |
| EP2558097B1 (en) | 2017-10-25 |
| AU2011241478A1 (en) | 2012-11-01 |
| ES2647223T3 (es) | 2017-12-20 |
| NZ603040A (en) | 2015-03-27 |
| CA2796207A1 (en) | 2011-10-20 |
| JP6148618B2 (ja) | 2017-06-14 |
| CN102844032A (zh) | 2012-12-26 |
| AU2011241478B2 (en) | 2016-12-01 |
| JP2013523844A (ja) | 2013-06-17 |
| KR20130106267A (ko) | 2013-09-27 |
| SG10201502391WA (en) | 2015-05-28 |
| CN105560245A (zh) | 2016-05-11 |
| US20110257192A1 (en) | 2011-10-20 |
| ZA201207696B (en) | 2014-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012110770A3 (en) | Combination of glycopyrrolate and a beta2 -agonist | |
| EA201190108A1 (ru) | Фармацевтическая композиция для ингаляции | |
| WO2015018840A3 (en) | Novel means to decrease the negative effects of smoking | |
| PH12015501108B1 (en) | Treatment of pulmonary disease | |
| JO3150B1 (ar) | مشتقات بيريدين و بيرازين لعلاج مرض cf | |
| ZA201303960B (en) | Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases | |
| NZ710726A (en) | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide | |
| HK1214159A1 (zh) | 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物 | |
| TW200708513A (en) | Novel crystalline forms of tiotropium bromide | |
| GEP20186885B (en) | Novel compounds | |
| GB2468073A (en) | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations | |
| WO2006117300A3 (en) | Crystalline forms of tiotropium bromide | |
| MX2017009091A (es) | Complejos de metal y desferroxiamina para el tratamiento de trastornos relacionados con la inmunidad. | |
| UA100777C2 (ru) | Вдыхаемые частички, содержащие тиотропий | |
| EA201290374A1 (ru) | Аэрозольная композиция для copd | |
| GB2496800A (en) | Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition | |
| EP3132799A4 (en) | Pharmaceutical composition comprising pistacia weinmannifolia extract, fraction of same or compound separated from same for preventing or treating chronic obstructive pulmonary disease (copd) | |
| WO2013098672A3 (en) | Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations | |
| EP2585067A4 (en) | COMPOUND FOR THE TREATMENT OF ENTEROVIRUS | |
| WO2005086915A3 (en) | Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor | |
| WO2009019598A3 (en) | Inhalation therapy for respiratory disorders | |
| MX2012011938A (es) | Compuesto para tratamiento de condicion o enfermedad respiratoria. | |
| WO2015023508A3 (en) | Methods for improving asthma symptoms using benralizumab | |
| MX2012002091A (es) | Uso de antibioticos en aerosol para el tratamiento de la enfermedad pulmonar obstructiva cronica. | |
| UA115989C2 (uk) | Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |